Earnings guidance for the second quarter of the fiscal year ending March 2027 has been revised upward. Revenue 4,360 million yen from 4,270 million yen, operating income 300 million yen from 170 million yen, ordinary income 310 million yen from 170 million yen, and net income for the period attributable to owners of parent 220 million yen from 120 million yen. Increases of 90 million yen, 130 million yen, 140 million yen, and 100 yen in per-share interim net income, respectively. Main reasons: higher sales of consumables both domestically and internationally and reduced selling, general and administrative expenses due to delayed recognition of R&D costs. No impact on full-year guidance. No change to dividend guidance.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"6678","jir_company_name":"TechnoMedica Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-08-05","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/6678-20260805-02.pdf","jir_short_summary":"Earnings guidance for the second quarter of the fiscal year ending March 2027 has been revised upward. Revenue 4,360 million yen from 4,270 million yen, operating income 300 million yen from 170 million yen, ordinary income 310 million yen from 170 million yen, and net income for the period attributable to owners of parent 220 million yen from 120 million yen. Increases of 90 million yen, 130 million yen, 140 million yen, and 100 yen in per-share interim net income, respectively. Main reasons: higher sales of consumables both domestically and internationally and reduced selling, general and administrative expenses due to delayed recognition of R&D costs. No impact on full-year guidance. No change to dividend guidance.","jir_summary":"### Overview of earnings guidance revision\nWe revised the earnings guidance for the second quarter of the fiscal year ending March 2027 (April 1, 2026\u2013September 30, 2026). All metrics\u2014revenue, operating income, ordinary income, interim net income, and interims per-share net income\u2014are upwardly revised, with particularly notable growth in operating income, ordinary income, and interim net income. The revision is primarily due to increased sales of consumables domestically and internationally and reduced SG&A expenses due to delayed recognition of R&D costs, and is not expected to affect the full-year earnings guidance. There is no change to the dividend guidance.\n\n### Outlook and notes\nThe revision applies only to the interim period, with no impact anticipated on the full-year guidance. While exchange rates at the time of disclosure are cited, the body does not include specific explanations of currency impact. Future performance may be influenced by market trends, timing of R&D costs, and promotional activities.","jir_financial_highlights":"Revenue: 4,360\u767e\u4e07\u5186 (\u524d\u56de\u767a\u8868\u4e88\u60f3(\uff21) 4,270\u767e\u4e07\u5186 \u2192 \u4eca\u56de\u4fee\u6b63\u4e88\u60f3(\uff22) 4,360\u767e\u4e07\u5186)\nOperating income: 300\u767e\u4e07\u5186 (\u524d\u56de\u4e88\u60f3170\u767e\u4e07\u5186 \u2192 \u4eca\u56de\u4e88\u60f3300\u767e\u4e07\u5186)\nOrdinary income: 310\u767e\u4e07\u5186 (\u524d\u56de\u4e88\u60f3170\u767e\u4e07\u5186 \u2192 \u4eca\u56de\u4e88\u60f3310\u767e\u4e07\u5186)\nNet income for the period attributable to owners of parent: 220\u767e\u4e07\u5186 (\u524d\u56de\u4e88\u60f3120\u767e\u4e07\u5186 \u2192 \u4eca\u56de\u4e88\u60f3220\u767e\u4e07\u5186)\nEarnings per share (interim): 31.90\u5186 (\u524d\u56de 17.40\u5186 \u2192 \u4eca\u56de 31.90\u5186)","jir_category":"","jir_hashtags":"#TechnoMedica, #earnings_guidance, #JapanEquities","jir_key_figures":"Revenue: 4,360\u767e\u4e07\u5186\uff08\u5bfe\u524d\u56de\u6bd4+2.1%\uff09\nOperating income: 300\u767e\u4e07\u5186\uff08\u5bfe\u524d\u56de\u6bd4+130\u767e\u4e07\u5186\uff09\nOrdinary income: 310\u767e\u4e07\u5186\uff08\u5bfe\u524d\u56de\u6bd4+140\u767e\u4e07\u5186\uff09","jir_meta_title":"TechnoMedica Inc. Increases Earnings Guidance | As of August 2026","jir_meta_description":"TechnoMedica Inc. revises its earnings guidance for the second quarter of the fiscal year ending March 2027. Revenue 4,360 million yen, operating income 300 million yen, ordinary income 310 million yen, interim net income attributable to owners of parent 220 million yen. No change to full-year guidance or dividend guidance; details provided.","jir_og_title":"Notice of Upward Revision to Earnings Guidance","jir_og_description":"TechnoMedica revises its interim earnings guidance. Revenue 4,360 million yen, operating income 300 million yen, etc., with no impact on full-year guidance. See IR materials for details.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":57947,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"earnings_guidance","footnotes":""},"sector":[],"importance":[],"class_list":["post-95529","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n